Dr. Reddy's Laboratories Ltd. Q3 FY2025 results: revenue ₹8,381 crore, up 15.8% on the year
Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹8,381 crore for Q3 FY2025, the quarter ended 31 December 2024, up 15.8% on the same quarter a year earlier. Profit after tax was ₹1,404 crore, up 1.7% on the year, and earnings per share ₹16.97. The figures are the company's own, from the unaudited results it filed with NSE on 24 January 2025.
The quarter, against the one before and a year earlier
| Line | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 8,381 | 8,038 | 7,237 | +15.8% |
| Other income | 150 | 308 | 216 | -30.5% |
| Total income | 8,531 | 8,346 | 7,453 | +14.5% |
| Cost of materials consumed | 1,453 | 1,287 | 1,141 | +27.3% |
| Purchases of stock-in-trade | 1,051 | 1,283 | 1,208 | -13.0% |
| Changes in inventories | 78 | -203 | -174 | n/a |
| Employee benefit expense | 1,366 | 1,399 | 1,276 | +7.1% |
| Finance costs | 82 | 76 | 39 | +107.4% |
| Depreciation, depletion and amortisation | 471 | 397 | 374 | +26.2% |
| Other expenses | 2,160 | 2,196 | 1,761 | +22.6% |
| Total expenses | 6,661 | 6,434 | 5,627 | +18.4% |
| Profit before exceptional items and tax | 1,870 | 1,911 | 1,826 | +2.4% |
| Exceptional items | 0 | 0 | 0 | n/a |
| Profit before tax | 1,870 | 1,911 | 1,826 | +2.4% |
| Current tax | 533 | 771 | 354 | +50.7% |
| Deferred tax | -63 | -196 | 94 | n/a |
| Total tax | 470 | 576 | 448 | +4.9% |
| Profit after tax | 1,404 | 1,342 | 1,381 | +1.7% |
| Attributable to owners of the parent | 1,414 | 1,256 | 0 | n/a |
| Other comprehensive income | -202 | 296 | 99 | n/a |
| Total comprehensive income | 1,202 | 1,638 | 1,480 | -18.8% |
| EPS, basic | ₹16.97 | ₹15.08 | ₹82.94 | -79.5% |
| EPS, diluted | ₹16.94 | ₹15.05 | ₹82.81 | -79.5% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 5,305 | 5,627 | 5,710 | 6,007 | 6,434 | 6,661 | 7,051 | 6,958 | 7,414 | 7,481 | 7,827 | 7,902 |
| Operating profit | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,887 | 382 | 860 |
| OPM % | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other income | 315 | 216 | 198 | 187 | 308 | 150 | 522 | 290 | 324 | 269 | 475 | 355 |
| Interest | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1,912 | 1,826 | 1,602 | 1,877 | 1,911 | 1,870 | 2,000 | 1,905 | 1,738 | 1,541 | 195 | 552 |
| Tax % | 23% | 25% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net profit | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS in ₹ | ₹89.09 | ₹82.94 | ₹78.66 | ₹83.61 | ₹15.08 | ₹16.97 | ₹19.12 | ₹17.04 | ₹16.18 | ₹14.53 | ₹2.65 | ₹5.33 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.
Source
Unaudited consolidated results for the quarter ended 31 December 2024, filed with NSE on 24 January 2025: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.